Item 8.01 Other Events.

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today completed its previously-announced underwritten public offering of 12,650,000 primary shares of common stock at a public offering price of $2.00 per share, including 1,650,000 shares purchased by the underwriter, Jefferies & Company, Inc., upon full exercise of the option granted it by the Company. Net proceeds to Progenics were approximately $23.3 million, after deducting underwriting discounts and commissions and estimated offering expenses. Jefferies acted as sole book-running manager for the offering, which utilized a portion of the Company's $100 million shelf registration statement, including a November 29, 2012 prospectus supplement.

---